Pfizer and BioNTech seek full vaccine approval for those ages 12-15

The Hill (12/16) reports that Pfizer and BioNTech announced on Thursday evening that they had submitted an application to the Food and Drug Administration (FDA) seeking full approval for the administration of their two-dose COVID-19 vaccine in children aged between 12 and 15. The companies said in a release that their application included follow-up data from their Phase 3 clinical trial, which showed that two doses of the vaccine were 100 percent effective against COVID-19 among 12 to 15-year-olds.

Pfizer and BioNTech seek full vaccine approval for those ages 12-15 | TheHill